Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

This open-label, phase I/II study investigated the safety and efficacy of epratuzumab, a humanised anti-CD22 monoclonal antibody, in the treatment of patients with active primary Sjögren's syndrome (pSS). Sixteen Caucasian patients (14 females/2 males, 33–72 years) were to receive 4 infusions o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Steinfeld, Serge D, Tant, Laure, Burmester, Gerd R, Teoh, Nick KW, Wegener, William A, Goldenberg, David M, Pradier, Olivier
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2006
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1779377/
https://ncbi.nlm.nih.gov/pubmed/16859536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar2018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados